BRIEF—Once-weekly Kyprolis better than twice-weekly, study shows

The results of the Phase III ARROW trial show that US biotech Amgen’s Kyprolis (carfilzomib) with dexamethasone is more effective in relapsed and refractory multiple myeloma at the once-weekly 70 mg/m2 dose than it is when administered at the 27 mg/m2 dose with dexamethasone.

This less frequent, stronger dosage gave patients in the trial an average of 3.6 months longer without their disease worsening, meaning the trial met its primary endpoint. The overall safety profile of the once-weekly Kyprolis regimen was comparable to that of the twice-weekly regimen.

The study included 478 patients with relapsed and refractory multiple myeloma who received two or three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.